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Axillary lymph node involvement is the best prognostic factor for breast cancer survival. Staging breast cancers by axillary
dissection remains standard management and is part of the UK national guidelines for breast cancer treatment. In the presence
of involved axillary lymph nodes best treatment has been shown to be axillary clearance (Fentiman and Mansell, 1991), but
clearly for women whose nodes are uninvolved avoidance of morbidity is optimal and this will be achieved by minimal
dissection of the axilla. Thus, for node-negative women the introduction of the sentinel node biopsy technique may
revolutionise the approach to the axilla. These will be women with mammographic screen detected small well and moderately
differentiated tumours (Hadjiloucas and Bundred, 2000). The impact of sentinel node biopsy in women who have
symptomatic large tumours is unproven, and around half of these women will require a second procedure to clear their axilla
or radiotherapy as treatment. Even for those women found to have involved sentinel lymph nodes the ability to use early
systemic chemotherapy followed by axillary clearance or radiotherapy may provide long-term survival gains. Sentinel node
biopsy should not, however, become routine practice until randomised controlled trials have proven its beneﬁt and safety in
reducing morbidity. Several randomised controlled trials (including ALMANAC) are currently underway.
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Sentinel node lymphoscintigraphy leads to the visualisation of hot
radioactive nodes in sites other than the axilla in about 13% of all
cases (range 2–35% in series using different injection techniques)
(Cserni and Szekeres, 2001). Tanis and co-workers in this issue of
the Journal report the detection of non-axillary sentinel nodes and
its impact on treatment. Earlier studies where internal mammary
(IM) lymph node dissection has been performed have shown IM
node involvement in about 23% of breast cancer patients (Cserni
and Szekeres, 2001). In the study by Tanis et al (this issue) the
proportion of detected non-axillary node metastases was about
5% among all patients, which is similar to ﬁndings in other studies
where lymphoscintigraphy has been used (Cserni and Szekeres,
2001; Dupont et al, 2001). Only patients with a visualised non-axil-
lary sentinel node were biopsied but this low proportion of
metastases might also reﬂect that breast cancer is detected at an
earlier stage today. The proportion of involved nodes was 20–
25% among those patients who underwent an IM or other non-
axillary sentinel node biopsy.
Centrally and medially located tumours have been reported to
have a higher proportion of IM lymph node metastases compared
to lateral tumours (Manji, 1982). However, in the overview of
series undergoing extended radical mastectomy (Cserni and
Szekeres, 2001) the range of IM lymph node involvement was
13.3–35.3% in lateral tumours and 19.5–32.6% in central and
medial tumours. Tumour location alone is therefore not a reliable
indicator of risk for IM lymph node metastases (Urban and Marja-
ni, 1971; Donegan, 1977; Noguchi et al, 1998, 2000; Sugg et al,
2000; Cserni and Szekeres, 2001; Dupont et al, 2001).
The detection of an involved sentinel node in non-axillary sites
(predominantly IM nodes) is not necessarily of prognostic value or
predictive of survival. The prognostic value of IM lymph node
involvement alone is similar to the value of axillary lymph node
involvement (Noguchi et al, 1993; Veronesi et al, 1999). However,
the importance of ﬁnding a non-axillary sentinel node will mainly
be dependent on it being the only involved node which occurs in
less than 10% of cases where the IM nodes are involved (Donegan,
1977; Jansen et al, 2000). A small proportion of axillary node nega-
tive patients have IM node metastases but today, we are not able to
predict which patients these are. The value of ﬁnding these metas-
tases remains to be determined both regarding prognosis and affect
on treatment decisions.
The detection of IM nodes or other non-axillary sentinel nodes
is largely dependent on the method of injection of isotope and the
use of lymphoscintigraphy to detect involved nodes. A peri-
tumoural injection technique visualises IM lymph nodes in about
15–30% of women, whereas subdermal or subareolar injection
of isotope does not seem to identify IM nodes (Kett et al, 1993;
Borgstein et al, 1997, 2000; Roumen et al, 1999; Cserni and
Szekeres, 2001; Shen et al, 2001; Tanis et al, 2001). The mammary
gland and the overlying skin clearly show a common lymphatic
pathway to the axilla and the same axillary sentinel node in most
cases (Dupont et al, 2001), but they do not appear to both drain
to the IM chain. The kinetics of different traces and the timing
of the injection before surgery are also issues that inﬂuence the
detection and successful localisation of an IM node, e.g. lymph
drains more slowly after a peri-tumoural injection compared to
after an intra-dermal sub-areolar injection. Furthermore, the preo-
perative intra-dermal injection of colloid blue dye quickly
disappears and makes it more difﬁcult to ﬁnd very small IM nodes
compared with an intra-tumoural or peri-tumoural injection espe- Received 14 June 2002; accepted 15 July 2002
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operation including axillary dissection and primary tumour exci-
sion. The use of blue dye alone should be discouraged as it gives
sub-optimal imaging for non-axillary sentinel nodes.
Although some authors have argued we should abandon
lymphoscintigraphy (McIntosh and Purushotham, 1998) because
most axillary sentinel nodes can be detected at operation by
gamma-probe, its discontinuation would preclude the detection
of IM nodes or non-axillary sentinel nodes. Thus, lymphoscintigra-
phy is particularly crucial for medial tumours in the breast in
young women less than 70 years of age where chemotherapy
may be indicated if a positive node is found in a non-axillary senti-
nel node but not in the axilla. However, it must also be recognised
the treatment decisions are based on tumour characteristics (Gold-
hirsch et al, 1995). Large size, high grade, hormone receptor
negativity and other prognostic factors generally indicate the need
for chemotherapy regardless of node status at present. The non-
axillary node status will still add information on prognosis for
these women but will not affect treatment decisions.
In the study by Tanis et al (this issue) patient management chan-
ged in 17% of patients with visualised non-axillary sentinel nodes.
However, this may be an overestimation of the importance of
non-axillary sentinel node biopsies. As shown in various rando-
mised studies comparing Halsted mastectomy with extended
mastectomy, the IM lymph node dissection by itself has no survival
beneﬁt (Lacour et al, 1976; Donegan, 1977; Veronesi et al, 1985,
1999). Another question to be answered is the role of radiotherapy
as treatment to the IM chain. Thus far radiotherapy has not
provided any survival advantage but the issue is still under study
and a large European trial EORTC 22922 is investigating the effects
of irradiation on the IM and medial supraclavicular lymph nodes in
terms of loco-regional control and survival (Lievens et al, 2001). The
routine practice in the department of Tanis et al (this issue) was to
irradiate the parasternal area if axillary nodes were involved. In a
large proportion of the cases where management ‘changed’ the use
of radiotherapy was decided on the basis of the IM node status; a
therapy that is unproven. Furthermore, eight out of 11 patients with
isolated non-axillary lymph node metastases had tumours larger
than 1 cm and would therefore have been offered adjuvant hormo-
nal treatment according to many treatment guidelines anyway. The
routine use of immunohistochemistry in addition to H&E staining
to detect nodal micro-metastases is not accepted practice in many
centres and additionally, the prognostic value of metastases lesser
than 2 mm in size is not proven (Yarbro et al, 1999). Thus the value
of treating such ﬁndings is unknown and itself justiﬁes a clinical trial
comparing adjuvant treatment with no adjuvant treatment for
women with nodal micro-metastases.
The beneﬁt of IM sentinel node biopsy has to be weighed
against the possible morbidity caused by surgery, as women who
undergo breast-conserving surgery will need a further medial inci-
sion over the sternum to biopsy the IM node. The lack of interest
in the IM node means that many surgeons today have no experi-
ence of the procedure nor have they had to deal with the
complications of the procedure such as haemo- or pneumothorax
(Bembenek and Schlag, 2000). However, a few studies have shown
that non-axillary sentinel node biopsy can be performed with few
side effects and a relatively high success ratio (Jansen et al, 2000;
Noguchi et al, 2000; Dupont et al, 2001) although this has to be
conﬁrmed in other centres and countries.
The value of detecting non-axillary lymph nodes by lymphoscin-
tigraphy potentially improves the rationale for individualising
optimal treatment strategy. Biopsy of an IM lymph node is neces-
sary if lymphoscintigraphy indicates it is the sentinel node, though,
it remains inappropriate to biopsy an IM node if it is not blue or
hot on lymphoscintigraphy as IM node biopsy is not routine prac-
tice. First and foremost, data from randomised trials are required
to demonstrate that sentinel node biopsy is reducing morbidity
in axillary surgery. Once such data is available we will be able to
determine if the identiﬁcation of non-axillary sentinel lymph nodes
contributes to treatment decisions signiﬁcantly.
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